A results day followed by a trading pause
Verici Dx plc (LSE:VRCI) published its half-year report on 30 September 2026 and, in the same evening, announced a proposed fundraise. By the next morning its shares had been temporarily suspended from trading on AIM under a Capital Access Window. The central question is why a transplant diagnostics company that raised money in June has returned to investors within four months, and what its first-half numbers reveal about that decision.
What Verici Dx does
Verici Dx develops and sells diagnostic tests intended to help clinicians manage kidney transplant patients. Its commercial product, Tutivia, is a test used after transplantation, and the company is also developing Protega, a further test on its pipeline, and TranscripTx, a genetic test it has said it will launch towards the end of 2026. Its customers are mainly US transplant centres, and the company reports in US dollars. In August it signed a Certified Service Provider agreement with Olink, extending its laboratory services offering.
The latest announcements
On 30 September 2026, Verici Dx said it intended to raise new capital through a bookbuild, with Singer Capital Markets and Oberon Investments acting as joint bookrunners. The company did not disclose the amount sought or the issue price, stating that the price would be determined after the bookbuild. It said the proceeds would be used to "expand the commercial team", for targeted Marketing and further working capital. On 1 October 2026, a regulatory notice confirmed that trading in the shares had been suspended at the company's request from 7.30am, pending a further announcement. The Capital Access Window mechanism is designed to give pricing stability while a bookbuild runs.
First-half performance
The half-year report showed Revenue of $1.8 million for the six months to 30 June 2026, slightly below $1.9 million a year earlier. That figure masks a shift in mix. Tutivia testing revenue rose 53% to $1.77 million, from $1.16 million, but the prior-year period had included $0.75 million of licensing income from Thermo Fisher that was not repeated. The company reported an adjusted EBITDA loss of $3.5 million, wider than $2.8 million, and a net loss of $4.0 million against $3.1 million.
Cash stood at $2.4 million at 30 June 2026, down from $3.3 million at the end of 2025, after an operating cash outflow of $3.8 million. Net Assets were $5.7 million. The June share placing brought in £2.6 million gross, or about $3.4 million.
Commercially, the company said 32 transplant centres were onboarded during the half, with 35 in total by the report date, and that 825 tests were ordered in the period. It also reported an agreement with Blue Cross and Blue Shield of Illinois covering Tutivia and the grant of an additional CPT PLA code for Protega, effective from 1 October 2026.
Risks and points to watch
The figures suggest the Business is still consuming cash faster than revenue is growing, which explains the reliance on share funding. The size and pricing of the new raise are unknown, so the degree of dilution for existing shareholders cannot yet be judged. The report also notes that Cash Flow forecasts depend on the timing of future commercial receipts and spending, "all of which are subject to uncertainty". Reimbursement levels, the pace of centre adoption and the timing of the TranscripTx launch are further variables.
Why the company is raising again
Verici Dx is returning to the market because its losses widened in the first half and cash fell to $2.4 million, even as Tutivia testing revenue grew sharply. The company has framed the new money as funding for a larger sales effort rather than survival, but the outcome of the bookbuild, and the terms attached to it, will determine how far it extends the company's runway.






Please wait processing your request...